Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC reduced its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 2.8% during the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 343,171 shares of the biopharmaceutical company's stock after selling 9,932 shares during the period. Segall Bryant & Hamill LLC owned approximately 0.28% of Halozyme Therapeutics worth $21,898,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of HALO. Heck Capital Advisors LLC purchased a new stake in shares of Halozyme Therapeutics in the fourth quarter valued at about $29,000. Bessemer Group Inc. boosted its holdings in shares of Halozyme Therapeutics by 62.9% in the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 207 shares in the last quarter. Park Place Capital Corp boosted its holdings in shares of Halozyme Therapeutics by 20.1% in the first quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company's stock valued at $69,000 after acquiring an additional 182 shares in the last quarter. UMB Bank n.a. boosted its holdings in shares of Halozyme Therapeutics by 267.4% in the first quarter. UMB Bank n.a. now owns 1,319 shares of the biopharmaceutical company's stock valued at $84,000 after acquiring an additional 960 shares in the last quarter. Finally, CWM LLC boosted its holdings in shares of Halozyme Therapeutics by 46.3% in the first quarter. CWM LLC now owns 1,383 shares of the biopharmaceutical company's stock valued at $88,000 after acquiring an additional 438 shares in the last quarter. 97.79% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CEO Helen Torley sold 20,000 shares of the company's stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $52.96, for a total transaction of $1,059,200.00. Following the completion of the transaction, the chief executive officer owned 733,719 shares of the company's stock, valued at approximately $38,857,758.24. This represents a 2.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Jeffrey William Henderson sold 4,497 shares of the company's stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $60.37, for a total transaction of $271,483.89. Following the transaction, the director directly owned 28,611 shares of the company's stock, valued at $1,727,246.07. This trade represents a 13.58% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 64,497 shares of company stock valued at $3,533,884. Company insiders own 2.40% of the company's stock.

Halozyme Therapeutics Trading Down 2.4%

Shares of NASDAQ:HALO traded down $1.36 during trading on Friday, reaching $56.45. The stock had a trading volume of 1,111,552 shares, compared to its average volume of 1,752,240. The business has a fifty day moving average price of $54.29 and a 200-day moving average price of $57.21. The company has a quick ratio of 7.30, a current ratio of 8.39 and a debt-to-equity ratio of 3.13. The stock has a market cap of $6.96 billion, a P/E ratio of 15.01, a PEG ratio of 0.39 and a beta of 1.15. Halozyme Therapeutics, Inc. has a fifty-two week low of $42.01 and a fifty-two week high of $70.51.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, beating analysts' consensus estimates of $0.98 by $0.13. The business had revenue of $264.86 million during the quarter, compared to analyst estimates of $231.21 million. Halozyme Therapeutics had a net margin of 44.76% and a return on equity of 136.91%. The company's revenue was up 35.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.79 earnings per share. As a group, analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Analyst Ratings Changes

HALO has been the topic of a number of research analyst reports. Leerink Partners downgraded shares of Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price objective on the stock. in a report on Tuesday, May 13th. The Goldman Sachs Group assumed coverage on shares of Halozyme Therapeutics in a report on Thursday, July 10th. They set a "neutral" rating and a $55.00 price objective on the stock. Morgan Stanley cut shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and cut their target price for the stock from $73.00 to $62.00 in a research report on Wednesday, May 14th. JPMorgan Chase & Co. lifted their target price on shares of Halozyme Therapeutics from $58.00 to $60.00 and gave the stock a "neutral" rating in a research report on Wednesday. Finally, Leerink Partnrs cut shares of Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Tuesday, May 13th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $62.70.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.